In Vivo Genetic Medicines Company
Transforming Gene Therapy from Complex to Accessible.
We are pioneering scalable in vivo genetic medicines through integrated manufacturing solutions—making "off-the-shelf" gene therapies a reality.
Our Science
Next-Generation Gene Delivery.
-
At the core of our approach is the L-Vivo Platform—a proprietary, stable HEK 293 cell line engineered for continuous, high-titer production of next-generation lentiviral vectors.
Unlike traditional transient transfection methods that limit scalability and drive up costs, our stable packaging cell line enables an "antibody-like" manufacturing process: consistent, reproducible, and scalable to meet clinical and commercial demand.
-
The cell and gene therapy industry has long faced a critical bottleneck—the inability to produce viral vectors at scale, cost-effectively. Our platform addresses this challenge head-on by combining advanced genomic engineering with purpose-built manufacturing systems.
-
Stable, continuous production of high-titer lentiviral vectors
Versatile pseudotyping for broad tropism (ex vivo) or ligand-directed targeting (in vivo)
Proprietary genome site-specific integration for precision in vivo genome modification
AI-integrated closed-system manufacturing for enhanced safety, yield, and consistency
What We Do
Two Integrated Pillars. One Mission.
We operate at the intersection of therapeutic innovation and manufacturing excellence—building medicines while enabling others to do the same.
-
We are advancing a focused pipeline of in vivo genetic medicines targeting high unmet need in oncology and rare diseases.
Our proprietary platform enables direct, in vivo delivery of therapeutic genetic payloads—bypassing the complexity and cost of traditional ex vivo cell engineering. This approach unlocks the potential for truly "off-the-shelf" gene therapies that can reach more patients, faster.
Focus Areas:
In vivo CAR-T and gene-modified cell therapies for haematological and solid tumour malignancies
Precision gene therapies for monogenic rare diseases
-
Leveraging our L-Vivo platform and deep manufacturing expertise, we provide end-to-end CDMO services for the global cell and gene therapy industry.
Our Offering:
Clinical and commercial-grade lentiviral vector production
Process development from bench to GMP manufacture
Regulatory-compliant quality control (QC) analytics
Target Product Quality Profile (TPQP) development for advanced therapies
Support for both L-Vivo platform-based and non-L-Vivo viral vector programs
We partner with biotechs, pharma, and academic sponsors to de-risk their programs and accelerate the path from discovery to clinic.
Who We Are
Experienced Leaders in Cell & Gene Therapy
Banyan Therapeutics was founded by a team with significant experience in establishing and operating therapeutics companies and contract development and manufacturing organisations (CDMOs) across the cell and gene therapy industry.
Our leadership brings over 50 combined years of expertise spanning viral vector development, GMP manufacturing, regulatory strategy, clinical translation, and commercial operations. We have built and scaled GMP facilities, led bench-to-bedside programs, advised regulatory authorities, and successfully operated publicly listed life sciences companies.
We are headquartered in Singapore, at the heart of Asia's rapidly growing biomedical ecosystem, with strategic partnerships that provide access to GMP cleanroom facilities and a pathway to global markets.
Our Commitment: To deliver scalable, accessible genetic medicines that transform outcomes for patients with cancer and rare diseases—while enabling our partners to do the same.
Contact Us
Interested in partnering with us or learning more about our platform?